Stroke


Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke

Link to the Inserm press review  (in French)


J.-L. Mas, G. Derumeaux, B. Guillon, E. Massardier, H. Hosseini, L. Mechtouff, C. Arquizan, Y. Béjot, F. Vuillier, O. Detante, C. Guidoux, S. Canaple, C. Vaduva, N. Dequatre‑Ponchelle, I. Sibon, P. Garnier, A. Ferrier, S. Timsit, E. Robinet‑Borgomano, D. Sablot, J.-C. Lacour, M. Zuber, P. Favrole, J.-F. Pinel, M. Apoil, P. Reiner, C. Lefebvre, P. Guérin, C. Piot, R. Rossi, J.-L. Dubois‑Randé, J.-C. Eicher, N. Meneveau, J.-R. Lusson, B. Bertrand, J.-M. Schleich, F. Godart, J.-B. Thambo, L. Leborgne, P. Michel, L. Pierard, G. Turc, M. Barthelet, A. Charles‑Nelson, C. Weimar, T. Moulin, J.-M. Juliard, and G. Chatellier, for the CLOSE Investigators*

Abstract


BACKGROUND

Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke would benefit from PFO closure or anticoagulation, as compared
with antiplatelet therapy.


METHODS


In a multicenter, randomized, open-label trial, we assigned, in a 1:1:1 ratio, patients 16 to 60 years of age who had had a recent stroke attributed to PFO, with an associated atrial septal aneurysm or large interatrial shunt, to transcatheter PFO closure plus long-term antiplatelet
therapy (PFO closure group), antiplatelet therapy alone (antiplatelet-only group), or oral anticoagulation (anticoagulation group) (randomization group 1). Patients with contraindications to anticoagulants or to PFO closure were randomly assigned to the alternative noncontraindicated treatment or to antiplatelet therapy (randomization groups 2 and 3). The primary outcome was occurrence of stroke. The comparison of PFO closure plus antiplatelet therapy with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 2, and the comparison of oral anticoagulation with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 3.


RESULTS


A total of 663 patients underwent randomization and were followed for a mean (±SD) of 5.3±2.0 years. In the analysis of randomization groups 1 and 2, no stroke occurred among the 23 patients in the PFO closure group, whereas stroke occurred in 14 of the 235 patients in the antiplatelet- only group (hazard ratio, 0.03; 95% confidence interval, 0 to 0.26; P<0.001). Procedural complications from PFO closure occurred in 14 patients (5.9%). The rate of atrial fibrillation was higher in the PFO closure group than in the antiplatelet-only group (4.6% vs. 0.9%, P = 0.02). The number of serious adverse events did not differ significantly between the treatment groups (P = 0.56). In the analysis of randomization groups 1 and 3, stroke occurred in 3 of 187 patients assigned to oral anticoagulants and in 7 of 174 patients assigned to antiplatelet therapy alone.

CONCLUSIONS


Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone. PFO closure was associated with an increased risk of atrial fibrillation. (Funded by the French Ministry of Health; CLOSE ClinicalTrials.gov number, NCT00562289.)


This part of the website could either be in French or English, depending on the sources of the actualities.

Autres Publications

 09 janvier 2019
In vivo Optogenetic Approach to Study Neuron-Oligodendroglia Interactions in Mouse Pups
 21 décembre 2018
Predictive Modulation of Corticospinal Excitability and Implicit Encoding of Movement Probability in Schizophrenia
 07 novembre 2018
Manual Dexterity and Aging: A Pilot Study Disentangling Sensorimotor From Cognitive Decline
 05 novembre 2018
Burnout in medical students before residency: A systematic review and meta-analysis
 03 octobre 2018
Tobacco Smoking and Psychotic-Like Experiences in a General Population Sample
 18 mai 2018
Memory circuits: CA2
 07 mai 2018
Cortical developmental death: selected to survive or fated to die
 05 avril 2018
Plasma amyloid levels within the Alzheimer’s process and correlations with central biomarkers
 02 mars 2018
Longitudinal Analyses of Blood Transcriptome During Conversion to Psychosis.
 15 février 2018
Mapping molecular assemblies with fluorescence microscopy and object-based spatial statistics
 14 février 2018
A disassembly-driven mechanism explains F-actin-mediated chromosome transport in starfish oocytes
 12 décembre 2017
The dynamics of stress: a longitudinal MRI study of rat brain structure and connectome.
 04 octobre 2017
Stroke
 20 septembre 2017
Soluble Amyloid Precursor Protein Alpha Interacts with alpha3-Na, K-ATPAse to Induce Axonal Outgrowth but Not Neuroprotection: Evidence for Distinct Mechanisms Underlying these Properties
 19 septembre 2017
Transient increase in sAPPa secretion in response to Ab1e42 oligomers: an attempt of neuronal self-defense?
 11 septembre 2017
Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol.
 01 juin 2017
Targeting demyelination via α-secretases promoting sAPPα release to enhance remyelination in central nervous system
 19 avril 2017
Spastin regulates VAMP7-containing vesicles trafficking in cortical neurons.
 05 avril 2017
Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in mice.
 14 mars 2017
Cognitive control deficit in patients with first-episode schizophrenia is associated with complex deviations of early brain development.